To explore the relationship between mouse double minute 2 binding protein (MTBP) and the prognosis of cancer patients, a databank-based reanalysis was conducted and a clinical observation about lung adenocarcinoma was taken to verify the result of data analysis.
Introduction
Mouse double minute 2 (MDM2) binding protein (MTBP) is a protein, which interacts with oncoprotein murine double minute (MDM2), located in chr8:120445426-120523635, confirmed by in situ hybridization, [1] a major inhibitor of the tumor suppressor p53. It is reported to play a vital role in the regulation of the G(1) checkpoint of the cell cycle through its interaction with p53. p53-independent cell proliferation can be arrested by the expression level of MTBP, which is in turn blocked by simultaneous overexpression of MDM2. [2] Furthermore, MTBP may have some effects on tumor metastasis in mice and upregulate migratory potential of mouse embryonic fibroblasts regardless of the presence of p53. [3, 4] With the development of science, more and more results showed that MTBP had p53-independent roles in tumorigenesis. Overexpression of MTBP is associated with poor prognosis of cancer patients. [5, 6] Cordon-Cardo et al reported that soft tissue sarcoma and bladder cancer patients with tumors having both mutant p53 and overexpression of MTBP had a worse prognosis than those patients with tumors just harboring p53 mutations, [7] confirming that MDM2 played a p53-independent role in tumor development. Agarwal et al established an orthotopic tumor cell transplantation assay using osteosarcoma cells to indicate that MTBP suppresses cell migration and filopodia formation by inhibiting actinin-4 (ACTN4), which enhanced the understanding of MTBP in suppression of tumorigenesis and metastasis.
In breast cancer specimens, overexpression of both MYC and MTBP was associated with a worse prognosis in 10-year survival of patients compared with MYC overexpression alone. MTBP was also frequently co-amplified with MYC in many human cancers. Mechanistic investigations implicated associations with TIP48/TIP49 as well as MYC in MTBP function in cellular transformation and the growth of human breast cancer cells. It means that MTBP functions with MYC to promote malignancy, identifying this protein as a novel general therapeutic target in human cancer. In a word, oncogenic protein MTBP interacts with MYC to promote tumorigenesis. [9] In hepatocellular carcinoma, MTBP was reported to inhibit migration and metastasis. [10] Thus, increasing evidence indicates the significance of MTBP in tumor progression. However, the relationship between MTBP and cancer patients was still poorly understood, especially in clinical practice. In order to conclude the role of MTBP among cancer patients, we downloaded the published data and made further analysis with the help of some online tools and data analysis software, then we collected histopathological sections of lung adenocarcinoma patients and performed immunohistochemical staining to further verify whether the results of the data analysis (GSE30219 and LUAD-TCGA) were correct.
Materials and methods

Data collection
We collected all the data mainly from International Cancer Genome Consortium, The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO), selecting keywords related to MTBP, cancer, and gene expression technologies. For TCGA, all data were downloaded at the gene level (level 3). RNA-Seq counts data were log 2 transformed. The characteristics of all the available downloaded data were displayed in Table 1 . A total of 112 lung adenocarcinoma tissue specimens and adjacent normal tissues were randomly collected from patients who received surgery for lung cancer at the Department of Cardiothoracic Surgery of An Yang Hospital of HeNan Province from January 2016 to February 2017 with the permission of Ethics Committee of our hospital. All the patients had not been treated with radiotherapy and chemotherapy before surgery. All tissues were histologically identified as adenocarcinoma, evaluated by 2 senior pathologists. Then, we took immunohistochemistry to make sure the expression status of MTBP protein.
Immunohistochemistry and evaluation of staining intensity
Formalin-fixed, paraffin-embedded tissues were cut into 4-mmthick slices, and were dewaxed in xylene, rehydrated, and graded ethanol solutions. Then, slices (4-mm thick) were used for immunohistochemistry with a monoclonal anti-MTBP antibody (1:500 dilution, Abcam, Cambridge, UK). Antigens, heating the histopathological sections at 100°C for 35 minutes in citrate solution (10 mmol/L, pH 6.0), were reclaimed. Then sections were cooled and immersed in methanol in the presence of 0.3% hydrogen peroxide for 15 minutes to block the endogenous peroxidase activity, subsequently rinsed in phosphate buffer saline (PBS) for 5 minutes, according to the immunohistochemistry kit. PBS was taken as negative controls instead of the primary antibody. The sections were then incubated with horseradish peroxidase-labeled goat against mouse/rabbit secondary antibody (Abcam). Diaminobenzene was adopted as the chromogen and hematoxylin as the nuclear counterstain. At last, slices were taken to be dehydrated, cleared, and mounted.
All of the staining was evaluated independently by 2 senior pathologists. In 10 randomly selected fields, the intensity of MTBP immunochemical staining and the percentage of stained cells were assessed. Intensity of expression was examined based on the MTBP immunopositivity of normal pneumocyte. Intensity of immunopositivity was classified as negative (absent; score 0), weak (decreased intensity, compared with normal pneumocytes; score 1), moderate (the same intensity as MTBP expression of normal pneumocytes; score 2), and strong (increased intensity, compared with MTBP expression of normal pneumocytes; score 3). Score 3 was defined as over-expression of MTBP.
Statistical analysis
We analyzed all the data with the help of online tools as bcGeneExMiner, GOBO, PrognoScan, ITTACA, KMPlot, Recurrence Online, Stata, and SurvExpress. SPSS 19.0 software was used for clinical data statistical analysis. The relation between the MTBP in tumor specimens and other patient characteristics was examined with Pearson chi-squared test. Overall survival was calculated from the onset of initial diagnosis to the observation deadline or death. The log-rank test was taken to evaluate survival time for different groups. P values of clinical information shown are 2-sided, and P < .05 was considered statistically significant.
Prognostic index (PI) and Harrell's concordance index (CI) were taken to evaluate for all the downloaded data by Stata and R programming technology. [11] [12] [13] Harrell's CI (C index) was used to assess the discriminating ability of the different PIs. We adopt a means to identify the risk groups splitting the ordered PI (higher values corresponding to higher risk) and then let the same number of samples in each group mark the number of risk groups. If there are 2 risk groups, we will set the PI to the median. Another method of delineating risk groups is to adopt an optimization algorithm for the ordered PI. If there are 2 groups, the log-rank test will be performed along all values of the arranged PI. Then, the minimum P value is considered as the segmentation point for the algorithm, which was mentioned by Deguo Xu in his paper. [14] This procedure is applicable to more than 2 groups, and a risk group is repeatedly optimized until no changes are found. All risk evaluation processes can be easily finished with online analysis tools, SPSS 19.0 software or Stata software. [15] In this survival analysis, the hazard ratio (HR) is the risk ratio of the terms stated by 2 levels of risk groups. Survival rate was plotted using KaplanMeier method and analyzed by using log-rank test method. The frequencies of categorical variables were compared using Pearson chi-squared or Fisher exact test, when appropriate. A value of P < .01 was considered to be statistical significant.
Results
Eleven thousand nine hundred seventy-three subjects with MTBP status information from 34 data groups, were shown and marked in Table 1 , whereas 22 included data which just displayed without MTBP information. In order to reveal the relationship between MTBP and the survival of cancer patients, we analyzed all the data with survival information first. We tried our best to perform Kaplan-Meier survival curve for risk groups, CI, and P Table 1 Characteristics and preliminary analysis results of all data. value of the log-rank testing equality of survival curves in every database with MTBP information, as recommended by Bovelstad and Borgan. [16] Among all the results, green color represents lowrisk groups and red color means high-risk groups. Of 34 data groups, 6 showed the statistical significant P value, which were marked in Table 1 . Kaplan-Meier survival curves of 6 risk groups can be seen in Fig. 1 . We conclude form the preliminary results that hyper expression of MTBP may be associated with the worse prognosis of glioblastoma, kidney cancer, and lung cancer patients.
The stratification analysis of GSE16011 was made according to survival, histology, grade, therapy, gender, and age of the tumor data. The overall Kaplan-Meier curve result was shown in Fig. 1A Figure 2A showed clinical information available related to risk group, PI, and outcome data, while a box plot across risk groups, including the P value testing for difference using t test was shown in Fig. 2C . The process of risk group optimization was displayed in Fig. 2B . The Log-Rank Equal Curves were obviously separated from each other in All the above results are just concluded from data analysis. In order to verify the authenticity and correctness of the above Fig. 5A and B) and adenocarcinoma tissue ( Fig. 5C-E) . The overexpression status of MTBP gene was displayed in Fig. 5E , marked as (+++). Overall, 49 patients were female and 63 were male. Twenty-six patients were shown to be Meier survival cures were obviously separated from each other, which the results of Fig. 6B are similar to the results of data group GSE30219. Patients receiving treatment had a better prognosis than patients who had not received any treatment (Fig. 6D) , while the differences among 3 treatment approaches, compared in pairs, were of no obvious significance (P = .305/ .457/.957).
Discussion
As is known to all, Glioblastoma multiforme (GBM) is an aggressive, invasive brain tumor with poor prognosis. [17] Although, surgical resection and chemoradiotherapy are taken to deal with GBM, 5-year survival rate is no more than 5% after initial diagnosis. [18] Conventional chemotherapy shows lower survival benefits in GBM patients because of poor blood-brain barrier penetration, tumor heterogeneity, intrinsic resistance, and nonspecific toxicity. [19] A lot of clinical trials were carried out in the past years, but the survival of patients had been improved little. [20] A lot of factors are thought to be associated with the development of gliomas, but the pathogenesis of gliomas is still to be further studied. [21, 22] Therefore, plenty of further researches are urgently required to find out novel therapeutic targets and develop more effective combination strategies for GBM treatment.
MTBP is a protein, which interacts with oncoprotein murine double minute (MDM2), a major inhibitor of the tumor suppressor p53. [1] It was reported to be associated with cancer in some mechanism research, [8] [9] [10] 23] scarcely involved in clinical trials. With the development of whole genome sequencing, more and more scientific problems related to pathogenic genes can be elucidated. [24] [25] [26] However, the expenditure of sequencing is too high to be widely used for every research team. So, we change the perspective of our study instead of sequencing. Plenty of data about MTBP related to cancers can be downloaded online, such as TCGA, GEO, and so on. We reanalyzed the downloaded data (17,517 samples) to make sure the relationship between the level of MTBP expression and the survival of cancer patients. The overall Log-Rank Equal Curves were obvious separated from each other in 6 data groups, especially in glioblastoma patients (involved 1396 samples), which P values of them were all of statistical significance. The detail of the results can be seen in Fig. 1 . Therefore, we can conclude from the preliminary result that MTBP gene may be an adverse signal for the survival of glioblastoma, kidney cancer, and lung adenocarcinoma cancer patients. GBM could be divided into mesenchymal, classical, neural, and proneural subtypes according to a gene expression-based molecular classification system, created by TCGA. [27] Three signaling pathways are frequently reported in GBM: receptor tyrosine kinase (RTK)/Ras/phosphoinositide 3-kinase (PI3K), p53, and retinoblastoma (Rb) signaling. These have led to a better understanding of the molecular mechanism of GBM and have revealed numerous important changes in genes and pathways, [28, 29] scarcely involved MTBP. MTBP is a major inhibitor of the tumor suppressor p53. [1] It may show its effects on GBM through p53 signal pathway. In order to get more information about MTBP, we put the data of GSE16011 into stratification. The results were gathered in Figs. 2 and 3 . Furthermore, some of the results, listed in Figs. 2E and 3F, supported our hypothesis that overexpression of MTBP is an adverse signal for the survival of glioblastoma patients.
Every year, there are almost 270,000 patients suffering from kidney cancer leading to 11,500 deaths. [30] A lot of genes linked with kidney cancer, such as VHL, MET, FLCN, TSC1, TSC2, NOD2, and TFE3, [14] were identified by genome researches and have significantly changed the ways in which patients with kidney cancer are treated. The VHL pathway had been admitted for the therapy of patients with advanced kidney cancer. More new genome researches, such as whole genome sequencing, gene expression patterns, and so on, will still be needed to carried out to get a complete understanding of the genetic basic mechanism of kidney cancer and the kidney cancer gene pathways and, most importantly, to provide the foundation for the development of effective forms of therapy for patients with the disease.
[31] The Log-Rank Equal Curve of KIPAN, displayed in Fig. 1D , revealed that expression of MTBP is bad for the survival of kidney patients, which may provide useful guidance for kidney cancer treatments in the future. MTBP may be a new therapy target for kidney cancer patients, though plenty of researches are still needed to elucidate the mechanism between MTBP and the prognosis of kidney cancers.
There are plenty of genes or RNA involved in the tumorigenesis of lung cancer, including PD-1, K-RAS, EGFR, VEGF, BRAF, ERK-2, which promotes the development of lung cancer treatments. [32] [33] [34] [35] [36] [37] However, it is the first time for the relationship between MTBP expression and the survival of lung cancer patients to be revealed by reanalysis of online sequencing data, shown in Fig. 1F patients, and displayed that overexpression of MTBP is an adverse event for the prognosis of patients. The stratification of GSE30219 was carried out according to stage and histology of the tumor, which revealed that the Log-Rank Equal Curves were separated from each other in subgroup of adenocarcinoma and stage I, listed in Fig. 4 . The above results are picked up only from simple data analysis, and the authenticity and credibility are still to be verified. Therefore, we selected 112 cases of lung adenocarcinoma patients clinical pathological sections for immunohistochemical staining, to further verify the reality of the above conclusions. Patient characteristics were summarized in Table 2 . Clinical tumor stage, overexpression of MTBP, and malignant pleural effusion, shown in Fig. 6A -C, are factors that have significant influence on the prognosis of patients, which the results of Fig. 5B are consistent with the results of data group GSE30219. It was further confirmed that MTBP gene hyper expression is unfavorable to the prognosis of lung adenocarcinoma cancer patients. Every year, the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology will update their recommendations for molecular testing for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors. [38, 39] EGFR status is always listed as the first recommended test. It means that effective biological predictors, such as EGFR, ROS-1, ALK, and so on, are extremely important for evaluating the prognosis of cancer patients. [40] [41] [42] Through the above data analysis results and some clinical validation results, we can infer that MTBP, similar to EGFR, may become an indicator to evaluate the prognosis of cancer in the future, especially in lung adenocarcinoma cancer patients. More basic research on MTBP gene and clinical validation trials need to be invested in order to further clarify the role of MTBP in the development, progression, and prognosis of cancer.
Conclusions
We can conclude that hyper expression of MTBP is an adverse event for the survival of glioblastoma, kidney cancer, and lung cancer patients, which has been clinically verified in lung cancer.
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